MISSISSAUGA, ON, May 3, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the first quarter of 2024 after the market close on Thursday, May 9, 2024. The Company will also hold a conference call on Friday, May 10, 2024 at 8:30 ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | May 10, 2024 |
TIME: | 8:30AM |
DIAL-IN NUMBER: | 416-764-8650 or 888-664-6383 |
REPLAY: | 416-764-8677 or 888-390-0541 Code:196164# |
Expires: May 17, 2024 | |
WEBCAST: |
Cipher Pharmaceuticals (TSX:CPH) (OTCQX:CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$12.39 |
| Daily Change: | -0.52 -4.03 |
| Daily Volume: | 51,836 |
| Market Cap: | C$317.430M |
May 08, 2025 April 29, 2025 November 07, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
